TTrialPathMatch Me to Trials
← Back to trials
RecruitingChronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

Eligible age

18+ yrs

Accepts

All genders

Locations

11 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a prospective, multicenter, randomized, controlled, double-blind clinical trial enrolling 300 adult subjects with chronic rhinosinusitis (CRS) with and without nasal polyps (CRSwNP and CRSsNP) indicated for endoscopic sinus surgery (ESS).

Sponsor: Airiver Medical, Inc.

You may qualify if…

  • ✓ 1. Male or female, aged ≥18 years
  • ✓ 2. Confirmed diagnosis of CRS per the 2021 "International Consensus Statement on Allergy and Rhinology: Rhinosinusitis" definition.
  • ✓ 3. Radiographic evidence of bilateral ethmoid disease on CT taken 6 months or less prior to study index procedure and at least 6 months after any prior ESS or nasal surgery, polypectomy, balloon sinus dilation, etc. as applicable
  • ✓ 4. Radiographic evidence of bilateral frontal sinus and/or frontal sinus outflow tract disease
  • ✓ 5. Baseline SNOT-22 score ≥ 30
  • ✓ 6. Has failed previous medical treatment and is an appropriate candidate for primary or revision ESS of bilateral ethmoid sinuses and bilateral frontal/frontal sinus outflow tract
  • ✓ 7. Willing and able to provide written informed consent
  • ✓ 8. Willing and able to comply with all protocol follow up visits and assessments

You may not qualify if…

  • ✕ 1. Nasal cavity tumor (malignant or benign)
  • ✕ 2. Antrochoanal polyps
  • ✕ 3. Previous complete middle turbinate resection
  • ✕ 4. Clinical evidence or suspicion of invasive fungal sinusitis (e.g., bone erosion on CT scan, necrotic sinus tissue)
  • ✕ 5. History of prior lamina dehiscence or cerebrospinal fluid (CSF) leak in skull-based dehiscence
  • ✕ 6. Concurrent condition requiring active chemotherapy and/or immunotherapy management
  • ✕ 7. Subjects whose symptoms are too severe to undergo ESS (e.g., temperature \>102.5F or extra-sinus manifestations, such as orbital cellulitis; dental or facial or brain abscess; cavernous vein thrombosis; or altered mental status
  • ✕ 8. History of complications from prior ESS or balloon dilation procedure (e.g., CSF leak or injury to the skull base or orbital injury)

Where it's recruiting

Alabama

Birmingham · Huntsville

California

San Diego

Colorado

Colorado Springs

Iowa

Cedar Rapids

Kansas

Kansas City

Kentucky

Louisville

New York

The Bronx

Pennsylvania

Philadelphia

South Carolina

Charleston

Texas

Dallas · Fort Worth · McKinney

Virginia

Charlottesville

Source: ClinicalTrials.gov · NCT07290140 · last updated 2026-10-29